Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 48

Drinking any amount of alcohol likely increases dementia risk

Drinking any amount of alcohol likely increases the risk of dementia, suggests the largest combined observational and genetic study to date, published in BMJ Evidence-Based Medicine.

Even light drinking—generally thought to be protective, based on observational studies—is unlikely to lower the risk, which rises in tandem with the quantity of alcohol consumed, the research indicates.

Current thinking suggests that there might be an “optimal dose” of alcohol for brain health, but most of these studies have focused on and/or didn’t differentiate between former and lifelong non-drinkers, complicating efforts to infer causality, note the researchers.

Hidden Plant Stem Cells Could Hold the Key to Feeding the Future

Plant scientists discovered hidden stem cell regulators tied to growth and crop size. Their breakthrough could transform how we grow food, fuel, and resilient harvests.

Plant stem cells play a vital role in producing the world’s food, livestock feed, and renewable fuels. They are the foundation of plant growth, yet many aspects of how they work remain a mystery. Past studies have struggled to identify several of the key genes that govern stem cell activity.

Mapping the genetic regulators of growth.

Scientists Advance Prospects for Permanently Putting AIDS Virus into Dormant State Using Gene Therapy

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a molecule within HIV itself can be manipulated and amplified to force the virus into long-term dormancy, a state in which HIV does not replicate.

The Johns Hopkins team that conducted the new study had previously shown that the molecule of interest, an “antisense transcript,” or AST, is produced by HIV’s genetic material and is part of a molecular pathway that essentially puts the virus to sleep, a state known as viral latency.

The study’s leader, Fabio Romerio, Ph.D., associate professor of molecular and comparative pathobiology at the Johns Hopkins University School of Medicine, says the new findings add to a growing body of evidence that may help researchers develop a gene therapy that boosts AST production. A report on the research, funded by the National Institutes of Health, was published May 9 in Science Advances.

Bilu Huang — CSO, Fuzhuang Therapeutics — Conquering Aging Via TRCS

Conquering aging via TRCS — the telomere DNA AND ribosomal DNA co-regulation model for cell senescence — bilu huang — CSO, fuzhuang therapeutics.

Bilu Huang (https://biluhuang.com/) is a visionary scientist dedicated to finding solutions to some of the most pressing challenges facing humanity. His interdisciplinary work spans multiple fields, including biological aging, dinosaur extinction theories, geoengineering for carbon removal, and controlled nuclear fusion technology.

Born in Sanming City, Fujian Province, Huang is an independent researcher whose knowledge is entirely self-taught. Driven by curiosity and a relentless pursuit of scientific exploration, he has achieved numerous research results through his dedication and passion for science.

As a talented theoretical gerontologist, he proposed the Telomere DNA and ribosomal DNA co-regulation model for cell senescence (TRCS) and he is now using this latest theory to develop biotechnology to rejuvenate cells which will be used to completely cure various age-related degenerative diseases and greatly extend human life at Fuzhuang Therapeutics (https://lab.fuzhuangtx.com/en/).

#Aging #Longevity #BiluHuang #FuzhuangTherapeutics #TelomereDNAAndRibosomalDNACoRegulationModelForCell #Senescence #TRCS #DinosaurExtinctionResearch #CarbonRemovalTechnology #ControlledNuclearFusion #TelomereDNA #RibosomalDNA #CellularAging #GeneticProgram #Telomere #P53

Continue reading “Bilu Huang — CSO, Fuzhuang Therapeutics — Conquering Aging Via TRCS” | >

How a key enzyme shapes nucleus formation in cell division

Every time a eukaryotic cell divides, it faces a monumental challenge: It must carefully duplicate and divide its genetic material (chromosomes) equally, and then rebuild the nuclear envelope around the separated halves. If this process goes wrong, the resulting nuclei can be misshapen or disorganized—features often seen in cancer and aging-related diseases.

A new study from researchers at the Indian Institute of Science (IISc) and Université Paris-Saclay reveals how a key enzyme called Aurora A helps cells pull off this feat. The findings are published in The EMBO Journal.

In dividing cells, structures called spindle poles (or centrosomes) grow in size to generate the microtubule ‘tracks’ that pull chromosomes apart. Once this job is done, the spindle poles must shrink and disassemble so that the can reform around the separated chromosomes.

The latest on nucleotide therapy development

Oligonucleotide therapies — engineered strands of DNA or RNA — are transforming modern medicine. These cutting-edge treatments bring a new level of precision in combating disease by targeting specific genes to be silenced, activated or edited. “Nucleotide therapeutics allow us to design predictable outcomes by modifying sequences to address almost any condition,” says Peter Guterstam, product manager at biotechnology company Cytiva.

Due to an influx of research in recent years, many nucleotide-based drug candidates, including genetic therapies and vaccines for cancer and viral infections, are now in advanced clinical trial stages. “The development timeline is much quicker than we are used to,” notes Guterstam.

Significant challenges arise during development of RNA and DNA based therapies. From mRNA vaccines to gene editing, scientists are refining delivery methods, optimizing synthesis, and tackling scaling hurdles.

Largest genetic study to date identifies 13 new DNA regions linked to dyslexia

Dyslexia is a neurodevelopmental condition estimated to affect between 5–10% of people living in most countries, irrespective of their educational and cultural background. Dyslexic individuals experience persistent difficulties with reading and writing, often struggling to identify words and spell them correctly.

Past studies with twins suggest that is in great part heritable, meaning that its emergence is partly influenced by inherited from parents and grandparents. However, the exact genetic variants (i.e., small differences in DNA sequences) linked to dyslexia have not yet been clearly delineated.

Researchers at University of Edinburgh, the Max Planck Institute for Psycholinguistics and various other institutes recently carried out the largest genome-wide association study to date exploring the genetic underpinnings of dyslexia. Their paper, published in Translational Psychiatry, identifies several previously unknown genetic loci that were found to be linked to an increased likelihood of experiencing dyslexia.

Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities

T cells can be reprogrammed with transgenic antigen recognition receptors, including chimeric antigen receptors and T cell receptors, to selectively recognize and kill cancer cells. Such adoptive T cell therapies are effective in patients with certain haematological cancers but challenges persist, including primary and secondary resistance, a lack of efficacy in patients with solid tumours, a narrow range of targetable antigens, and time-consuming and complex manufacturing processes. CRISPR-based genome editing is a potent strategy to enhance cellular immunotherapies. Conventional CRISPR–Cas9 systems are useful for gene editing, transgene knock-in or gene knockout but can result in undesired editing outcomes, including translocations and chromosomal truncations. Base editing and prime editing technologies constitute a new generation of CRISPR platforms and enable highly precise and programmable installation of defined nucleotide variants in primary T cells. Owing to their high precision and versatility, base editing and prime editing systems, hereafter collectively referred to as CRISPR 2.0, are advancing to become the new standard for precision-engineering of cellular immunotherapies. CRISPR 2.0 can be used to augment immune cell function, broaden the spectrum of targetable antigens and facilitate streamlined production of T cell therapies. Notably, CRISPR 2.0 is reaching clinical maturity, with multiple clinical trials of CRISPR 2.0-modified cellular therapies currently ongoing. In this Review, we discuss emerging CRISPR 2.0 technologies and their progress towards clinical translation, highlighting challenges and opportunities, and describe strategies for the use of CRISPR 2.0 to advance cellular immunotherapy for haematological malignancies and solid tumours in the future.

#CRISPR9

Several persistent challenges limit the efficacy and applicability of adoptive T cell therapies for cancer, including suboptimal function and/or persistence in vivo, a narrow range of targetable antigens and complex manufacturing processes. This Review discusses the potential of ‘CRISPR 2.0’ precision gene-editing platforms, such as base editing and prime editing to address all of these challenges, and describes the progress made towards clinical translation of these technologies.

/* */